i-manager Publications

Pharmacoeconomics, Economics and Humanistic Outcomes

Rehan Haider*, Asghar Mehdi**, Geetha Kumari Das***, Zameer Ahmed****, Sambreen Zameer*****

* Department of Pharmacy, University of Karachi, Pakistan.

** Department of Pharmacology, Fazaia Ruth Pfau Medical College, Air University, Karachi, Pakistan.

*** OPJS University, Rajasthan, India.

****-***** Department of Pathology, Dow University of Health Sciences, Karachi, Pakistan.

Periodicity:September - December'2024

Abstract

Pharmacoeconomics is a branch of health economics that evaluates the prices and results of pharmaceutical products and services. It entails studying the monetary effect of various healthcare interventions, treatments, and guidelines to optimize aid allocation and improve patient effects. One important factor in pharmacoeconomics is its consciousness of both monetary and humanistic consequences. Financial consequences in pharmacoeconomics embody cost effectiveness, value-benefit analysis, and price minimization analysis. These metrics evaluate the economic implication of healthcare interventions, comparing the costs incurred with the benefits gained in terms of stepped-forward health outcomes. By assessing the monetary efficiency of various treatment options, policymakers and healthcare carriers could make informed choices about aid allocation, making sure that confined healthcare sources are used effectively. However, humanistic results in pharmacoeconomics emphasize the patient's first-class quality of life, delight, and usual well-being. Those outcomes cross past conventional economic measures, the non-public stories and options of patients. Humanistic effects may additionally include elements including pain relief, functional popularity development, and psychological well-being. By incorporating those affected person-focused consequences into pharmacoeconomic critiques, policymakers and healthcare providers can better understand the actual global effect of healthcare interventions on sufferers' lives.

Keywords

Pharmacoeconomics, Economics, Humanistic Consequences, Healthcare Interventions, Value- Effectiveness, Quality of Lifestyles, Patient Pleasure, Aid Allocation, Healthcare Guidelines, Selection-Making.

How to Cite this Article?

Haider, R., Mehdi, A., Das, G. K., Ahmed, Z., and Zameer, S. (2024). Pharmacoeconomics, Economics and Humanistic Outcomes. i-manager's Journal on Economics & Commerce, 4(3), 44-57.

References

[1]. Aaronson, N. K. (1989). Quality of life assessment in clinical trials: Methodologic issues. Controlled Clinical Trials, 10(4), 195-208.

[2]. American College of Clinical Pharmacy. (2024). Pharmacoeconomics and Outcomes: Applications for Patient Care.

[3]. Anderson, R., & Shemilt, I. (2010). The role of economic perspectives and evidence in systematic review. Evidence Based Decisions and Economics: Health Care, Social Welfare, Education and Criminal Justice (pp. 23-42).

[4]. Bootman, J. L., Townsend, R. J., & McGhan, W. F. (1996). Introduction to Pharmacoeconomics. Principles of Pharmacoeconomics.

[5]. Bowling, A. (1995). Measuring Disease: A Review of Disease-Specific Quality of Life Measurement Scales. Bioethics Research Library.

[6]. Bowling, A. (2017). Measuring Health: A Review of Subjective Health, Well-Being and Quality of Life Measurement Scales. Open University Press.

[7]. Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press.

[8]. Eddy, D. M., Hasselblad, V., & Shachter, R. (1990). An introduction to a Bayesian method for meta-analysis: The confidence profile method. Medical Decision Making, 10(1), 15-23.

[9]. Feldstein, P. J. (1983). Health Care Economics. Wiley.

[10]. Gelber, R.D., & Gelber, S. (1995). Quality-of-life assessment in clinical trials. In Thall, P.F. (eds) Recent Advances in Clinical Trial Design and Analysis, 75, 225-246. Springer.

[11]. Gold, M. (1996). Panel on cost-effectiveness in health and medicine. Medical Care, 34 (12), DS197- DS199.

[12]. Graves, N., Halton, K., & Lairson, D. (2007). Economics and preventing hospital-acquired infection: Broadening the perspective. Infection Control & Hospital Epidemiology, 28(2), 178-184.

[13]. Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., ... & Loder, E. (2013). Consolidated health economic evaluation reporting standards (CHEERS) statement. Bmj, 346, 1-6.

[14]. Jennings, B. M., & Staggers, N. (1997). The hazards in outcomes management. Outcomes Manage, 4(1), 18-23.

[15]. Jolicoeur, L. M., Jones-Grizzle, A. J., & Boyer, J. G. (1992). Guidelines for performing a pharmacoeconomic analysis. American Journal of Hospital Pharmacy, 49(7), 1741-1747.

[16]. Kozma, C. M., Reeder, C. E., & Schulz, R. M. (1993). Economic, clinical, and humanistic outcomes: A planning model for pharmacoeconomic research. Clinical Therapeutics, 15(6), 1121-32.

[17]. Lee, J. T., & Sanchez, L. A. (1991). Interpretation of “cost-effective" and soundness of economic evaluations in the pharmacy literature. American Journal of Hospital Pharmacy, 48(12), 2622-2627.

[18]. Lipscomb, J., Snyder, C. F., & Gotay, C. C. (2007). Cancer outcomes measurement: Through the lens of the Medical Outcomes Trust framework. Quality of Life Research, 16, 143-164.

[19]. Morgan, S., & Yoder, L. H. (2012). A concept analysis of person-centered care. Journal of Holistic Nursing, 30(1), 6-15.

[20]. Muennig, P., & Bounthavong, M. (2016). Cost-Effectiveness Analysis in Health: A Practical Approach. John Wiley & Sons.

[21]. Neumann, P. J., Cohen, J. T., & Weinstein, M. C. (2014). Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. New England Journal of Medication, 371(9), 796-797.

[22]. Patrick, D. L., & Deyo, R. A. (1989). Generic and disease-specific measures in assessing health status and quality of life. Medical Care, 27(3), S217-S232.

[23]. Sederer, L. I., Dickey, B., & Eisen, S. V. (1997). Assessing outcomes in clinical practice. Psychiatric Quarterly, 68, 311-325.

[24]. Tan-Torres Edejer, T., Baltussen, R., Adam, T., Hutubessy, R., Acharya, A., Evans, D.B., & Murray, C.J.L. (2003). Making Selections in Health: WHO Guide to Fee- Effectiveness Evaluation. World Health Employer.

[25]. Thurman, D. J., Kobau, R., Luo, Y. H., Helmers, S. L., & Zack, M. M. (2016). Health-care access among adults with epilepsy: The US national health interview survey, 2010 and 2013. Epilepsy & Behavior, 55, 184-188.

[26]. Tonin, F. S., Aznar-Lou, I., Pontinha, V. M., Pontarolo, R., & Fernandez-Llimos, F. (2021). Principles of pharmacoeconomic analysis: The case of pharmacist- led interventions. Pharmacy Practice (Granada), 19(1).

[27]. Townsend, R. J., Osterhaus, J. T., & Boyer, J. G. ( 2010 ) . Pharmacoeconomics: Economic and humanistic outcomes. Principles and Practice of Pharmaceutical Medicine (pp. 315-325).

[28]. Wailoo, A. J., Hernandez-Alava, M., Manca, A., Mejia, A., Ray, J., Crawford, B., ... & Busschbach, J. (2017). Mapping to estimate health-state utility from non–preference-based outcome measures: An ISPOR good practices for outcomes research task force report. Value in Health, 20(1), 18-27.

[29]. Ware Jr, J. E. (1995). The status of health assessment 1994. Annual Review of Public Health, 16(1), 327-354.

[30]. Wilkins, E. G., Lowery, J. C., & Smith Jr, D. J. (1996). Outcomes research: A primer for plastic surgeons. Annals of Plastic Surgery, 37(1), 1-11.

[31]. Zarkin, G. A., Bala, M. V., Wood, L. L., Bennett, C. L., Simpson, K., & Dohn, M. N. (1996). Estimating the cost effectiveness of atovaquone versus intravenous pentamidine in the treatment of mild-to-moderate Pneumocystis carinii pneumonia. Pharmacoeconomics, 9, 525-534.

Pharmacoeconomics, Economics and Humanistic Outcomes

Abstract

Keywords

How to Cite this Article?

References

If you have access to this article please login to view the article or kindly login to purchase the article

Purchase Instant Access

Options for accessing this content:

	North Americas,UK, Middle East,Europe		India	Rest of world
	USD	EUR	INR	USD-ROW
Pdf	35	35	200	20
Online	35	35	200	15
Pdf & Online	35	35	400	25